Influence of unrecognized molecular heterogeneity on randomized clinical trials.
about
Micro-NMR for rapid molecular analysis of human tumor samplesThe clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunitiesStatistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practiceAdvances in diagnostic and treatment modalities for intracranial tumors.Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.DNA-encoded antibody libraries: a unified platform for multiplexed cell sorting and detection of genes and proteins.Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease.Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.Effective incorporation of biomarkers into phase II trialsPhase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer TherapiesDevelopment of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.The macrophage colony-stimulating factor 1 response signature in breast carcinomaIdentification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis.Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.Gefitinib in non small cell lung cancerIDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resectionOligodendroglioma: toward molecular definitions in diagnostic neuro-oncology.Rethinking clinical trials for cytostatic drugs.A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens.Chemotherapy of anaplastic oligodendroglial tumours.Development and use of biomarkers in oncology drug development.Drug development in oncology: classical cytotoxics and molecularly targeted agents.Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer.DNA-microarray analysis of brain cancer: molecular classification for therapy.Breast cancer gene expression profiling: clinical trial and practice implications.Heterogeneity of Metastatic Melanoma: Correlation of MITF With Its Transcriptional Targets MLSN1, PEDF, HMB-45, and MART-1.Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.Angiogenic inhibitors: a new therapeutic strategy in oncology.Multidomain patient-reported outcomes of irritable bowel syndrome: exploring person-centered perspectives to better understand symptom severity scores.Hormonal treatment of human hepatocellular carcinoma.Is human hepatocellular carcinoma a hormone-responsive tumor?Targeting targeted agents: open issues for clinical trial designMiniaturized nuclear magnetic resonance platform for detection and profiling of circulating tumor cellsHeterotransplant mouse model cohorts of human malignancies: A novel platform for Systematic Preclinical Efficacy Evaluation of Drugs (SPEED)The effect of heterogeneity on HIV prevention trials.Neurofibrillary Tangle Stage and the Rate of Progression of Alzheimer Symptoms: Modeling Using an Autopsy Cohort and Application to Clinical Trial Design.Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?Identification of biomarker-by-treatment interactions in randomized clinical trials with survival outcomes and high-dimensional spaces.Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring.
P2860
Q24603587-0B2F463B-81C2-42FC-AE6B-56C25D076ACEQ27025579-70F67428-BF1A-4527-A984-0A1E054AAF5AQ28078729-822B852B-571C-4487-9526-70E499F3A18FQ30358150-332F2019-1DF3-4E78-87D1-0BED88C26358Q30542081-56D693C3-E731-4EF3-9F0E-7344592F1324Q33270725-37B722B4-3021-409F-94B8-3311D118B28FQ33677196-006A4E91-D44B-403A-B123-CB2B25A2BD76Q33723651-844AC288-4732-41AA-9192-CF97D0F3733BQ33870594-E53605A7-FC3B-4A05-AB15-5AEDDD61514DQ33985780-7DA0934A-E902-47A8-8309-6AE4824D86ECQ34316288-3FAC51DC-1407-425C-A802-63A22D2E867FQ34330564-07D7E9B5-97F4-4000-BDB8-1AB488A7F274Q34624405-3BAD6FA4-E553-4EED-95C2-B22037C67C36Q34993367-D7FD9BBE-3A49-4F47-AD5C-A7B875CD0479Q35031807-E8E16F1B-8238-4B28-8BAA-E28EC32D1D3FQ35059157-071AE02A-403A-4518-8E17-0DFBB58D5A77Q35063647-0DC83567-3FF0-4EDA-B389-7E7B70750648Q35166825-B425562D-93D9-4558-A984-7126D7BDDDE6Q35186717-091A00FD-82B5-4A90-9111-51D325B90B0AQ35680586-F5144B37-DFB6-49EB-BD50-7E6F92230AFBQ35812532-9DD08472-9B29-41E8-BE9C-95658A0A1E13Q35827606-1CBB8081-237A-444C-BAC3-2EDE500FCCDFQ35836427-C3C2A0E9-8BC6-4218-95D3-D09F4DCFDA48Q35892040-537F7B21-FE1B-46E9-9324-2CD044FCD787Q36050579-1B450E2E-88FF-4B42-9D57-8024D77E5D0CQ36102231-73B8360D-7734-4B5C-9516-C090DCF1411CQ36135604-EFF9B5AF-D94C-47F8-94DD-88F679FA055BQ36246336-A3D34627-AB7B-4CF3-9ACD-1C769BAD86A6Q36306264-C0A42FB5-D011-4D2D-BFC6-D7AEB7F06C13Q36573807-D7697D6A-B60C-4CA3-8578-BB5DB0EF9DC7Q36721771-679072DC-90DB-45B5-8016-49129E645D68Q37113547-1CCC0582-ECE6-46C4-A997-50E6E8A87059Q37229389-C5B16FD8-FDFD-41D6-8798-3540D9A6EFCFQ37351130-53207E3E-3243-4DC9-8084-7F17768BCC43Q37418880-263CBABB-1124-4935-97A9-AE140A6B4BA6Q37863367-E0B894F9-BEF8-4228-94E7-5622B5BE4FB1Q38911065-0470BA77-2D4C-4264-A41C-B5CE2450A5E5Q38933836-6B02F706-F7B9-45AB-BCB5-E2C6C92B8C7EQ39175273-504F8D88-D00C-4B9F-8715-F90AF4864FB3Q40042764-EF9186CA-5ADD-418D-B400-08EF4199C2B0
P2860
Influence of unrecognized molecular heterogeneity on randomized clinical trials.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Influence of unrecognized molecular heterogeneity on randomized clinical trials.
@en
Influence of unrecognized molecular heterogeneity on randomized clinical trials.
@nl
type
label
Influence of unrecognized molecular heterogeneity on randomized clinical trials.
@en
Influence of unrecognized molecular heterogeneity on randomized clinical trials.
@nl
prefLabel
Influence of unrecognized molecular heterogeneity on randomized clinical trials.
@en
Influence of unrecognized molecular heterogeneity on randomized clinical trials.
@nl
P2093
P356
P1476
Influence of unrecognized molecular heterogeneity on randomized clinical trials.
@en
P2093
David N Louis
J Gregory Cairncross
Rebecca A Betensky
P304
P356
10.1200/JCO.2002.06.140
P407
P577
2002-05-01T00:00:00Z